This article is part of Harvard Medical Schoolscontinuing coverageof medicine, biomedical research, medical education and policy related to the SARS-CoV-2 pandemic and the disease COVID-19.
What makes SARS-CoV-2, the virus behind COVID-19, such a threat?
A new study in Cell led by researchers at Harvard Medical School, Boston Children's Hospital and MIT pinpoints the likely cell types the virus infects.
Get more HMS news here
The study also unexpectedly showed that one of the bodys main defenses against viral infections may actually help the virus infect those very cells.
The study, published as a peer-reviewed pre-proof, will help focus efforts to understand what SARS-CoV-2 does in the body, why some people are more susceptible, and how best to search for treatments, the researchers say.
Multiple research models
When news broke about a new coronavirus in China, Jose Ordovas-Montanes, assistant professor of pediatrics at HMS and Boston Childrens, and colleague Alex Shalek at MIT had already been studying different cell types from throughout the human respiratory system and intestine. They also had gathered data from primates and mice.
In February, they began diving into these data.
We started to look at cells from tissues such as the lining of the nasal cavity, the lungs and gut, based on reported symptoms and where the virus has been detected, said Ordovas-Montanes, who is co-senior author of the new study along with Shalek. We wanted to provide the best information possible across our entire spectrum of research models.
Recent research had found that SARS-CoV-2, like the closely related SARS-CoV that caused the SARS pandemic, uses a receptor called ACE2 to gain entry into human cells, aided by an enzyme called TMPRSS2.
That led Ordovas-Montanes, Shalek and colleagues to ask a simple question: Which cells in respiratory and intestinal tissue express both ACE2 and TMPRSS2?
To get the answer, the team turned to single-cell RNA sequencing. This identifies which of roughly 20,000 genes are on in individual cells.
They found that only a tiny percentage of human respiratory and intestinal cellsoften well below 10 percentmake both ACE2 and TMPRSS2.
Those cells fall into three types: goblet cells in the nose that secrete mucus; lung cells known as type II pneumocytes that help maintain the alveoli (the sacs where oxygen is taken in); and one type of so-called enterocytes that line the small intestine and are involved in nutrient absorption.
Sampling from non-human primates showed a similar pattern of susceptible cells.
Many existing respiratory cell lines may not contain the full mix of cell types, and may miss the types that are relevant, said Ordovas-Montanes. Once you understand which cells are infected, you can start to ask, How do these cells work? Is there anything within these cells that is critical for the viruss life cycle?
"With more refined cellular models, we can perform better screens to find what existing drugs target that biology, providing a stepping stone to go into mice or non-human primates.
Interferon: Helpful or harmful?
But it was the studys second finding that most intrigued the scientists.
They discovered that the ACE2 gene, which encodes the receptor SARS-CoV-2 uses to enter human cells, is stimulated by interferonone of the bodys main defenses when it detects a virus.
Interferon actually turned on the ACE2 gene at higher levels, potentially giving the virus new portals to get in.
ACE2 is also critical in protecting people during various types of lung injury, said Ordovas-Montanes. When ACE2 comes up, thats usually a productive response. But since the virus uses ACE2 as a target, we speculate that it might be exploiting that normal protective response.
Interferons, in fact, are being tested as a treatment for COVID-19. Whether they would help or do more harm than good is not yet clear.
It might be that in some patients, because of the timing or the dose, interferon can contain the virus, while in others, interferon promotes more infection, said Ordovas-Montanes. We want to better understand where the balance lies, and how we can maintain a productive antiviral response without producing more target cells for the virus to infect.
ACE inhibitors and cytokine storms
The findings may also raise new lines of inquiry around ACE inhibitors. These drugs are commonly used to treat hypertension, which has been linked to more severe COVID-19 disease. Are ACE inhibitors affecting peoples risk?
ACE and ACE2 work in the same pathway, but they actually have different biochemical properties, Ordovas-Montanes said. Its complex biology, but it will be important to understand the impact of ACE inhibitors on peoples physiological response to the virus.
Its also too soon to try to relate the study findings to the cytokine storm, a runaway inflammatory response that has been reported in very sick COVID-19 patients.
Cytokines are a family of chemicals that rally the bodys immune responses to fight infections. Interferon is part of the family.
It might be that were seeing a cytokine storm because of a failure of interferon to restrict the virus to begin with, so the lungs start calling for more help," he said. "Thats exactly what were trying to understand right now.
In addition, the team wants to explore what SARS-CoV-2 is doing in the cells it targets and to study tissue samples from children and adults to understand why COVID-19 is typically less severe in younger people.
Carly Ziegler, Samuel Allon and Sarah Nyquist of MIT and Harvard and Ian Mbano of the Africa Health Research Institute were co-first authors on the paper. The study was done in collaboration with the Human Cell Atlas Lung Biological Network.
This has been an incredible community effort not just within Boston, but also with collaborators around the world who have shared their unpublished data to try and make potentially relevant information available as rapidly as possible, said Shalek. Its inspiring to see how much can be accomplished when everyone comes together to tackle a problem.
This work was supported in part by the National Institutes of Health (U24AI118672, AI201700104, R56AI139053, R01GM081871, T32GM007753, AI078908, HL111113, HL117945, R37AI052353, R01AI136041, R01HL136209, U19AI095219, U19HL129902, UM1AI126623, U19AI051731, R01HL095791, R33AI116184, U19AI117945, UM1AI126617), Bill and Melinda Gates Foundation, MIT Stem Cell Initiative through Foundation MIT, Aeras Foundation, Damon Runyon Cancer Research Foundation (DRG-2274-16), Richard and Susan Smith Family Foundation, UMass Center for Clinical and Translational Science Project Pilot Program, Office of the Assistant Secretary of Defense for Health Affairs (W81XWH-15-1-0317), P.B. Fondation pour la Recherche Medicale (DEQ20180339158) and Agence Nationale pour la Recherche (ANR-19-CE14-0027).
Adapted from a post in Discoveries, the Boston Children's clinical and research innovation portal.
- HRMC to open hematology and oncology clinic - The Ottawa Herald - June 29th, 2020
- Gift of Life, Root and Rutgers Researchers Launch COVID-19 Study - Patch.com - June 29th, 2020
- Obituaries in the Sunday and Monday Courier, June 28-29 - Waterloo Cedar Falls Courier - June 29th, 2020
- Efforts at coronavirus vaccines and treatments abound in the Bay Area - San Francisco Chronicle - June 23rd, 2020
- New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring's Plinabulin - GlobeNewswire - June 23rd, 2020
- [Herald Interview] Spinning cord blood into stem cell therapies - The Korea Herald - June 22nd, 2020
- Children's Hospital Los Angeles Ranked No. 1 Children's Hospital in the Western U.S., No. 5 Nationally for Second Straight Year - Business Wire - June 22nd, 2020
- The BCG a Tuberculosis Vaccine Boosts Immune Cells and Reduces Risk of Other Infections - Gilmore Health News - June 18th, 2020
- FDA Approves Second Biomarker-Based Indication for Merck's KEYTRUDA (pembrolizumab), Regardless of Tumor Type - The Baytown Sun - June 17th, 2020
- UCLA receives nearly $14 million from NIH to investigate gene therapy to combat HIV - Mirage News - June 17th, 2020
- Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy - Stockhouse - June 17th, 2020
- UChicago working on COVID-19 saliva test Pandemic energizes health care unions Rehab hospital to be built in Libertyville - Crain's Chicago Business - June 17th, 2020
- UofL researchers to study health impacts of vaping, nicotine on youth - The Lane Report - June 14th, 2020
- Houston coronavirus updates: What you need to know about June 14 - msnNOW - June 14th, 2020
- Be The Match Appoints Amy Ronneberg as Chief Executive Officer - Southernminn.com - June 11th, 2020
- A&B could become premier stem cell producer - Antigua ... - June 11th, 2020
- Nick Cordero Had a 'Rocky Night' After He 'Spiked a Fever' During His Hospitalization, Wife Says - PopCulture.com - June 11th, 2020
- R3 International Now Offering New Stem Cell Therapy Program for Lyme Disease in Mexico - Yahoo Finance - June 10th, 2020
- Nick Cordero's Wife Says His COVID-19 Recovery Is 'Going in the Right Direction' - countryliving.com - June 10th, 2020
- Memorial Sloan Kettering - Hackensack Meridian Health Partnership Announces Funding for Inaugural Immunology Research Collaboration Projects - The... - June 10th, 2020
- Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells - Yahoo Finance - June 3rd, 2020
- Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research - WhaTech Technology and Markets News - June 3rd, 2020
- Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells | DNA RNA and Cells | News... - June 2nd, 2020
- CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases - P&T Community - June 2nd, 2020
- New Leaders at ASTCT and CIBMTR Provide Guidelines and Measures for Combating COVID-19 and Protecting Transplant Patients - Business Wire - June 2nd, 2020
- Exceptional stem cell science on tap for ISSCR 2020 Virtual June 23-27, 2020 - 7thSpace Interactive - June 2nd, 2020
- CAR T-Cell Therapy Impresses in Indolent NHL - MedPage Today - June 1st, 2020
- In situ repair abilities of human umbilical cordderived mesenchymal stem cells and autocrosslinked hyaluronic acid gel complex in rhesus monkeys with... - May 23rd, 2020
- UH studying use of convalescent plasma to improve health of COVID-19 patients - Crain's Cleveland Business - May 23rd, 2020
- COVID-19: Recommendations for Treating MS and Related... : Neurology Today - LWW Journals - May 21st, 2020
- New hybrid embryos are the most thorough mixing of humans and mice yet - Science News - May 20th, 2020
- Hotel in Spain requires two negative Covid-19 tests to check in with a free antibody test during your stay - CNBC - May 20th, 2020
- 'Outpatient Is Still Chaos': What We Heard This Week - MedPage Today - May 20th, 2020
- Sumit Dewanjee, MD, is being recognized by Continental Who's Who - PRNewswire - May 7th, 2020
- Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine - BioSpace - May 7th, 2020
- COVID-19 Impact and Recovery Analysis | Global Cell Isolation Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and Becton,... - May 7th, 2020
- Stem Cell Alopecia Treatment Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026 - 3rd Watch News - May 7th, 2020
- AMC to use stem cell therapy in treating graft-versus-host disease - Korea Biomedical Review - May 7th, 2020
- Drumming class finds a new rhythm with creative connections - Yes! Weekly - May 7th, 2020
- Drumming class finds a new rhythm with creative connections - Wake Forest University News Center - May 5th, 2020
- Insights on the Worldwide Cell Expansion Industry to 2027 - Analysis and Forecasts - Yahoo Finance UK - May 5th, 2020
- These 5 Houston-area research institutions have bright minds at work to battle COVID-19 - InnovationMap - May 5th, 2020
- GCC Condemns Israeli Plans to Annex Parts of the West Bank - Asharq Al-awsat English - May 2nd, 2020
- Jerusalem residents concerned Israel is changing their residency rights - Arabnews - May 2nd, 2020
- Four UTSW Researchers Named to The National Academy of Sciences - D Magazine - May 1st, 2020
- CHMP Grants Positive Opinion for DARZALEX (daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma - Yahoo Finance - May 1st, 2020
- Verify the URL - InnovationMap - May 1st, 2020
- Houston banking exec shares tips for keeping online information secure amid COVID-19 threats - InnovationMap - May 1st, 2020
- Trials and Tribulations: Neurology Research During COVID-19 - Medscape - April 30th, 2020
- Five UC San Diego Professors Elected to National Academy of Sciences - UC San Diego Health - April 29th, 2020
- Suffering from ED? Discover how our combined treatments of Hormone Balancing and FDA Approved Acoustic Wave Pulse Therapy Ends Your ED - Magazine of... - April 29th, 2020
- BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT - BioSpace - April 29th, 2020
- What Is The Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting? - AJMC.com Managed Markets Network - April 24th, 2020
- Healing the heart by returning it to its infancy - FierceBiotech - April 24th, 2020
- What Factors Influence Hematological Recovery in Patients Who Receive CAR-T Therapies? - Cancer Therapy Advisor - April 24th, 2020
- Academy adds new members from UW who 'expand the boundaries of knowledge' - University of Wisconsin-Madison - April 24th, 2020
- FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments - FDA.gov - April 24th, 2020
- A rampage through the body - Science Magazine - April 24th, 2020
- Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post - April 21st, 2020
- Stem Cell Therapy: A Promising Treatment for COVID-19? - Technology Networks - April 21st, 2020
- Meet the 5 female finalists for the 2020 M&T Bank John Travers Award - PennLive - April 21st, 2020
- Hackensack Meridian Health Studying the Blood of COVID-19 Survivors - The Ritz Herald - April 15th, 2020
- Reviewing the Latest Treatment Strategies in Patients with Transplant-Eligible Multiple Myeloma - Hematology Advisor - April 9th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2026 | Takeda Pharmaceutical Company Limited, Cytori... - April 9th, 2020
- Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development - Business Wire - April 9th, 2020
- 3 drug candidates authorized to treat COVID-19 patients - Korea Biomedical Review - April 7th, 2020
- Surgeon offers innovative treatments - Brunswick News - April 7th, 2020
- Health Tech: Dallas-based American Heart Association Awards $14M in Research Grants for Heart, Brain, and COVID-19 Innovation - dallasinnovates.com - April 7th, 2020
- Metrion Biosciences and International Scientific Consortium Publish Data and New Recommendations for in Vitro Risk Assessment of the Cardiac Safety of... - April 7th, 2020
- YOUR HEALTH: Something fishy to help improve eyesight - WQAD.com - April 6th, 2020
- First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency... - April 6th, 2020
- Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular... - April 6th, 2020
- Coronavirus Business Tracker: How The Private Sector Is Fighting The COVID-19 Pandemic - Forbes - April 6th, 2020
- Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients - Associated Press - April 6th, 2020
- Coronavirus daily news update, April 6: What to know today about COVID-19 in the Seattle area, Washington state and the nation - Seattle Times - April 6th, 2020
- Celularity and Infectious Disease Research Institute will try out COVID-19 cell therapy - GeekWire - April 3rd, 2020
- Pinprick Blood Test To Identify Antibodies In Patients Approved By FDA - Kaiser Health News - April 3rd, 2020
- CytoDyn CEO Dr. Pourhassan to Appear on Fox Business Network Friday, April 3, 2020 at 2:00 pm ET to Discuss Leronlimab Treatment of 10 Severely Ill... - April 3rd, 2020
- Is There a New CAR T-Cell Treatment for Mantle Cell Lymphoma? - AJMC.com Managed Markets Network - April 3rd, 2020
- North Jersey hitting the surge - Politico - April 3rd, 2020